Skip to Main Content

Author Details

Neil E Fleshner
University of Toronto
1989
554
72
PMIDPaper TitleJournal TitlePublished Year
37696743Limitations of Prostate Biopsy in Detection of Cribriform and Intraductal Prostate Cancer.Eur Urol Focus2024
37558528Addition of Cribriform and Intraductal Carcinoma Presence to Prostate Biopsy Reporting Strengthens Pretreatment Risk Stratification Using CAPRA and NCCN Tools.Clin Genitourin Cancer2024
36343786UGT2B28 accelerates prostate cancer progression through stabilization of the endocytic adaptor protein HIP1 regulating AR and EGFR pathways.Cancer Lett2023
378519132023 Canadian Urological Association guideline: Genetic testing in prostate cancer.Can Urol Assoc J2023
37685670Prevalence and Prognostic Implications of PSA Flares during Radium-223 Treatment among Men with Metastatic Castration Resistant Prostate Cancer.J Clin Med2023
37730609Clinical and dosimetric outcomes of image-guided, dose-painted radiotherapy in muscle invasive bladder cancer.Radiat Oncol2023
37606994Increasing trend of utilising active surveillance for Gleason Score 7â¿¿(3â¿¿+â¿¿4) prostate cancer.BJU Int2023
37494320Quantitative and qualitative impact of physician assistants in a Canadian urology setting.Can Urol Assoc J2023
37461140Poly(adenosine diphosphate-ribose) polymerase inhibitor combinations in first-line metastatic castrate-resistant prostate cancer setting: a systematic review and meta-analysis.BJU Int2023
37187202Radical cystectomy versus trimodality therapy for muscle-invasive bladder cancer: a multi-institutional propensity score matched and weighted analysis.Lancet Oncol2023
371852112023 American Society of Clinical Oncology Genitourinary (ASCO-GU) Cancers Symposium Meeting highlights.Can Urol Assoc J2023
37211455Development, multi-institutional external validation, and algorithmic audit of an artificial intelligence-based Side-specific Extra-Prostatic Extension Risk Assessment tool (SEPERA) for patients undergoing radical prostatectomy: a retrospective cohort study.Lancet Digit Health2023
37439809Neoadjuvant Cabazitaxel plus Abiraterone/Leuprolide Acetate in Patients with High-Risk Prostate Cancer: ACDC-RP Phase II Trial.Clin Cancer Res2023
37103562Cost of Bladder Cancer Care: A Single-center Comparison of Radical Cystectomy and Trimodal Therapy.Urol Pract2023
37007631Adherence to oral hormonal therapy in advanced prostate cancer: a scoping review.Ther Adv Med Oncol2023
37433574Mesorectal nodal metastasis with seminal vesicle invasion in biochemically recurrent prostate cancer.BJU Int2023
37268513Lymphotropic Pattern of Prostate-specific Membrane Antigen-detected Metastases Among Biochemically Recurrent Radical Prostatectomy Patients with Cribriform Disease.Eur Urol Focus2023
36994854Niraparib with Abiraterone Acetate and Prednisone for Metastatic Castration-Resistant Prostate Cancer: Phase II QUEST Study Results.Oncologist2023
36842920Urologic Oncology Survivorship Guidelines: An Overview of the Evidence and the Current Implementation Gap.Eur Urol Focus2023
36737311Long-Term Biochemical Control of a Prospective Cohort of Prostate Cancer Patients Treated With Interstitial Brachytherapy Versus Radical Prostatectomy.Clin Oncol (R Coll Radiol)2023
36639336Validating the total cancer location density metric for stratifying patients with low-risk localized prostate cancer at higher risk of grade group reclassification while on active surveillance.Urol Oncol2023
36702705Age related differences in primary testicular lymphoma: A population based cohort study.Urol Oncol2023
36792385Re: Sensitivity of Multiparametric MRI and Targeted Biopsy for Detection of Adverse Pathologies (Cribriform Gleason Pattern 4 and Intraductal Carcinoma): Correlation of Detected and Missed Prostate Cancer Foci with Whole Mount Histopathology.Eur Urol2023
32605887Determining the Impact of Spatial Heterogeneity on Genomic Prognostic Biomarkers for Localized Prostate Cancer.Eur Urol Oncol2022
35708696Enzalutamide Monotherapy vs Active Surveillance in Patients With Low-risk or Intermediate-risk Localized Prostate Cancer: The ENACT Randomized Clinical Trial.JAMA Oncol2022
35676330Impact of cribriform pattern 4 and intraductal prostatic carcinoma on National Comprehensive Cancer Network (NCCN) and Cancer of Prostate Risk Assessment (CAPRA) patient stratification.Mod Pathol2022
35507051Prostate biopsy in the era of MRI-targeting: towards a judicious use of additional systematic biopsy.Eur Radiol2022
35732815An appraisal of genetic testing for prostate cancer susceptibility.NPJ Precis Oncol2022
35537905Salvage partial gland ablation for recurrent prostate cancer following primary partial gland ablation: Functional and oncological outcomes.Urol Oncol2022
35437219Variability in testosterone measurement between radioimmunoassay (RIA), chemiluminescence assay (CLIA) and liquid chromatography-tandem mass spectrometry (MS) among prostate cancer patients on androgen deprivation therapy (ADT).Urol Oncol2022
35855558The role of prophylactic prostatectomy as a primary prevention strategy in high-risk germline mutation carriers.Curr Opin Urol2022
35754788Expansion of Lymphocytes from Prostatic Adenocarcinoma and Adjacent Nonmalignant Tissue.Prostate Cancer2022
35691034Time trends for drug specific adverse events in patients on sunitinib; implications for remote monitoring.Can J Urol2022
35393232The prognostic value of urinary cytology after trimodal therapy (TMT) for muscle-invasive bladder cancer.Urol Oncol2022
35621292Androgen deprivation therapy for prostate cancer: Prescribing behaviors and preferences among urologists.Can Urol Assoc J2022
366566942022 UPDATE: Canadian Urological Association-Canadian Urologic Oncology Group guideline: Metastatic castration-naive and castration-sensitive prostate cancer Full-text.Can Urol Assoc J2022
36449294Statin Use and Survival Among Men Receiving Androgen-Ablative Therapies for Advanced Prostate Cancer: A Systematic Review and Meta-analysis.JAMA Netw Open2022
35905298The effect of lowering cholesterol through diet on serum prostate-specific antigen levels: A secondary analysis of clinical trials.Can Urol Assoc J2022
36240332Recommendations for the implementation of genetic testing for metastatic prostate cancer patients in Canada.Can Urol Assoc J2022
36031465Extended Results and Independent Validation of a Phase 2 Trial of Metastasis-Directed Therapy for Molecularly Defined Oligometastatic Prostate Cancer.Int J Radiat Oncol Biol Phys2022
363785722022 Canadian Urological Association (CUA)-Canadian Uro Oncology Group (CUOG) guideline: Management of castration-resistant prostate cancer (CRPC).Can Urol Assoc J2022
36083240Low-grade prostate cancer should still be labelled cancer.BJU Int2022
34980879Have we mis-PRONOUNCEd the cardiovascular risk of GnRH agonists? A critical appraisal of the PRONOUNCE trial.Prostate Cancer Prostatic Dis2022
35182588Opioid Use After Nephrectomy for Kidney Cancer in Ontario: A Population-Based Study.Urology2022
35151601Combining CAPRA-S With Tumor IDC/C Features Improves the Prognostication of Biochemical Recurrence in Prostate Cancer Patients.Clin Genitourin Cancer2022
34941486The association of statin subgroups with lower urinary tract symptoms following a prostate biopsy.Can Urol Assoc J2022
34878188Prevalence of adverse pathology features in grade group 2 prostatectomy specimens with syn- or metachronous metastatic disease.Prostate2022
35205755Clinical Management of Prostate Cancer in High-Risk Genetic Mutation Carriers.Cancers (Basel)2022
35174071Investigating Urinary Circular RNA Biomarkers for Improved Detection of Renal Cell Carcinoma.Front Oncol2022
34872785Re: Jeremy Yuen-Chun Teoh, Daniele Castellani, Claudia Mercader, et al. A Quantitative Analysis Investigating the Prevalence of "Manels" in Major Urology Meetings. Euro Urol 2021;80:442-9.Eur Urol2022
  • 1 - 50 of 554

Recommended Authors

Giovanni Motterle
Mayo Clinic
Career Start Year 2017
Number of shared co-authors 15
Adam B Weiner
Northwestern University Feinberg School of Medicine
Career Start Year 2013
Number of shared co-authors 23
Devin N Patel
university of california san diego School of Medicine
Career Start Year 2011
Number of shared co-authors 5
Izak Faiena
Columbia University Medical Center
Career Start Year 2010
Number of shared co-authors 2
Alastair D Lamb
University of Oxford
Career Start Year 2007
Number of shared co-authors 58
Roderick C N van den Bergh
St. Antonius Hospital
Career Start Year 2007
Number of shared co-authors 18
Declan G Murphy
Peter MacCallum Cancer Centre, University of Melbourne
Career Start Year 2005
Number of shared co-authors 57
Jonathan L Wright
University of Washington Medical Center
Career Start Year 2005
Number of shared co-authors 38
Amirali Salmasi
University of California San Diego
Career Start Year 2005
Number of shared co-authors 7
Channing J Paller
Johns Hopkins University School of Medicine
Career Start Year 2004
Number of shared co-authors 20
Thorsten Schlomm
Charite - University Hospital Berlin
Career Start Year 2004
Number of shared co-authors 39
Anne Y Warren
Cambridge University Hospitals National Health Service Foundation Trust
Career Start Year 2003
Number of shared co-authors 55
Tim Dudderidge
University Hospital Southampton NHS Foundation Trust
Career Start Year 2002
Number of shared co-authors 43
Alberto Briganti
IRCCS San Raffaele Scientific Institute
Career Start Year 2002
Number of shared co-authors 58
Mark C Markowski
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Career Start Year 2001
Number of shared co-authors 14
Tomasz M Beer
OHSU Knight Cancer Institute, Oregon Health & Science University
Career Start Year 2000
Number of shared co-authors 51
Eleni Efstathiou
Houston Methodist Cancer Center
Career Start Year 2000
Number of shared co-authors 43
Vincent J Gnanapragasam
University of Cambridge
Career Start Year 1999
Number of shared co-authors 32
Evan Y Yu
University of Washington and Fred Hutchinson Cancer Research Center
Career Start Year 1997
Number of shared co-authors 55
Inge M van Oort
Radboud University Medical Center
Career Start Year 1995
Number of shared co-authors 33
Robert E Reiter
David Geffen School of Medicine at university of california los angeles
Career Start Year 1993
Number of shared co-authors 57
Choung-Soo Kim
Asan Medical Center, University of Ulsan College of Medicine
Career Start Year 1993
Number of shared co-authors 8
Raymond S Lance
Washington State University Elson S. Floyd College of Medicine
Career Start Year 1992
Number of shared co-authors 28
Byung Ha Chung
Yonsei University College of Medicine and Gangnam Severance Hospital
Career Start Year 1992
Number of shared co-authors 14
Paul L Nguyen
Brigham and Women's Hospital and Dana Farber Cancer Institute, Harvard Medical School
Career Start Year 1990
Number of shared co-authors 69
Anthony V D'Amico
Duke University Medical Center
Career Start Year 1988
Number of shared co-authors 37
Philip Cornford
Liverpool University Hospitals
Career Start Year 1988
Number of shared co-authors 13
Mark Frydenberg
Monash University
Career Start Year 1988
Number of shared co-authors 50
Alan W Partin
The Brady Urological Institute, Johns Hopkins University School of Medicine
Career Start Year 1987
Number of shared co-authors 75
Anders Bjartell
Skane University Hospital, Lund University
Career Start Year 1987
Number of shared co-authors 58

Collaborators

Antonio Finelli
Princess Margaret Cancer Centre, University Health Network and University of Toronto
Co-authored papers 156
Alexandre R Zlotta
University Health Network, Princess Margaret Cancer Center, University of Toronto
Co-authored papers 125
Girish S Kulkarni
Princess Margaret Cancer Centre, University Health Network, University of Toronto
Co-authored papers 107
Theodorus H van der Kwast
University Health Network, University of Toronto
Co-authored papers 94
Andrew J Evans
Princess Margaret Cancer Center, University Health Network.
Co-authored papers 61
John Trachtenberg
University of Toronto, University Health Network
Co-authored papers 49
Ants Toi
Mount Sinai Hospital, University of Toronto
Co-authored papers 39
Alejandro Berlin
University of Toronto, Princess Margaret Cancer Centre
Co-authored papers 38
Bharati Bapat
Mt Sinai Hospital
Co-authored papers 35
Fred Saad
University of Montreal Health Center
Co-authored papers 23
Martin E Gleave
University of British Columbia
Co-authored papers 20
Robert G Bristow
University of Toronto
Co-authored papers 18
Katherine Lajkosz
Princess Margaret Hospital
Co-authored papers 18
Armen Aprikian
McGill University Health Centre, McGill University
Co-authored papers 17
Masoom A Haider
University Health Network
Co-authored papers 16
Ekaterina Olkhov-Mitsel
University of Toronto
Co-authored papers 16
Joseph L Chin
University of Western Ontario
Co-authored papers 16
Cynthia Kuk
Mount Sinai Hospital, University of Toronto, University Health Network
Co-authored papers 16
George Tomlinson
University Health Network
Co-authored papers 15
Ken J Kron
Princess Margaret Cancer Centre, University Health Network
Co-authored papers 12
Kim N Chi
University of British Columbia
Co-authored papers 12
Anthony M Joshua
The Kinghorn Cancer Centre, St. Vincent's Hospital Sydney
Co-authored papers 11
David Robert Siemens
Queen's University
Co-authored papers 11
Dominique Trudel
Institut du cancer de Montreal
Co-authored papers 9
Renu Jeyapala
Toronto Metropolitan University
Co-authored papers 9
Karen Chadwick
University Health Network, University of Toronto
Co-authored papers 9
Monique J Roobol
Erasmus MC Cancer Institute, University Medical Center Rotterdam
Co-authored papers 9
Gerald L Andriole
Co-authored papers 9
Rachel M Glicksman
University of Toronto, Princess Margaret Cancer Centre, University Health Network
Co-authored papers 9
Danny Vesprini
University of Toronto, Canada Odette Cancer Centre
Co-authored papers 9
Release 1.2